Natixis Lowers Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Natixis cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 47.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,206 shares of the medical research company's stock after selling 5,541 shares during the period. Natixis' holdings in IQVIA were worth $1,220,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. MetLife Investment Management LLC boosted its position in IQVIA by 1.3% in the 4th quarter. MetLife Investment Management LLC now owns 46,670 shares of the medical research company's stock valued at $9,171,000 after buying an additional 588 shares during the period. Norinchukin Bank The boosted its holdings in IQVIA by 11.8% in the fourth quarter. Norinchukin Bank The now owns 8,248 shares of the medical research company's stock valued at $1,621,000 after purchasing an additional 872 shares during the period. Ossiam increased its holdings in IQVIA by 9.8% during the 4th quarter. Ossiam now owns 11,999 shares of the medical research company's stock worth $2,358,000 after purchasing an additional 1,074 shares during the period. Dimensional Fund Advisors LP raised its position in IQVIA by 18.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,387,862 shares of the medical research company's stock valued at $272,744,000 after purchasing an additional 214,046 shares in the last quarter. Finally, First Trust Advisors LP boosted its stake in shares of IQVIA by 15.3% in the 4th quarter. First Trust Advisors LP now owns 59,966 shares of the medical research company's stock valued at $11,784,000 after buying an additional 7,969 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of several analyst reports. Citigroup reduced their target price on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Morgan Stanley increased their target price on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. decreased their price target on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a report on Tuesday, February 18th. Finally, Stifel Nicolaus dropped their price objective on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $237.62.

IQVIA Stock Performance

Shares of IQV traded up $1.08 during mid-day trading on Tuesday, hitting $151.21. 181,078 shares of the company's stock were exchanged, compared to its average volume of 1,418,819. The firm has a market capitalization of $26.66 billion, a P/E ratio of 20.11, a P/E/G ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a fifty-two week low of $135.97 and a fifty-two week high of $252.88. The business's 50 day moving average is $170.67 and its two-hundred day moving average is $193.00. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.